The Study
Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial
This study is like a fair test where half the kids got a new vitamin and half got a sugar pill, and then doctors measured their hearts with super-accurate scans. They found the vitamin didn't make their aorta grow slower or their valve calcify less. So we can say this vitamin didn't help in this group — but we don't know if it might help other kids with different hearts.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Some people are born with a heart valve that has two flaps instead of three. This can make their aorta (the big blood vessel from the heart) slowly grow bigger over time. Doctors thought giving a cholesterol-lowering pill might help stop that.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 590 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though the pill worked to lower cholesterol, it didn’t slow down the aorta’s growth or prevent new calcium buildup on the valve — meaning the pill didn’t help with the main problem.
- 2After 3 years, the pill lowered cholesterol by 30 points, but the aorta grew the same amount in both the pill group and the placebo group — about 0.7 mm per year.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Circulation
Year
2024
Authors
Arturo Evangelista, L. Galian-Gay, A. Guala, G. Teixidó-Turà, F. Calvo-Iglesias, Teresa Sevilla, Javier Bermejo, I. Méndez, Violeta Sánchez, J. R. Robredo Carmona, J. Alegret, E. Ferrer-Sistach, Daniel Saura, A. Ruiz-Muñoz, L. Dux-Santoy, María Ángeles Carmona, M. Huguet, H. Cuellar-Calabria, Augusto Sao-Avilés, I. Ferreira-González, J. Rodríguez-Palomares
Related Content
Claims (6)
In adults with a bicuspid aortic valve and no initial calcification, taking 20 mg of atorvastatin daily for three years is associated with a lower rate of new calcification development compared to taking a placebo, though the difference was not statistically confirmed.
In adults with a bicuspid aortic valve and no severe heart dysfunction, the aorta expands by about 0.23 millimeters per year when measured with computed tomography, which is slower than earlier measurements made with echocardiography.
In adults with a bicuspid aortic valve and no severe valve problems, taking 20 mg of atorvastatin daily for three years does not slow the widening of the ascending aorta, even though it lowers LDL cholesterol levels.
In adults with a bicuspid aortic valve and no severe calcification, taking 20 mg of atorvastatin daily for three years does not slow the buildup of calcium in the aortic valve, even though it lowers LDL cholesterol significantly.
In adults with a bicuspid aortic valve and no severe valve problems, taking 20 mg of atorvastatin every day for three years lowers LDL cholesterol by 30 mg/dL on average compared to taking a placebo.
Statins increase calcium buildup in arteries while lowering the risk of heart attacks and strokes by making atherosclerotic plaques more stable.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.